Search Results 1231-1240 of 18234 for Topical

1. Mayo Clinic Q and A: Top tips to avoid back injuries this winter

   Topical agents, as well as heat and cold compresses, also can help. Gentle lower back therapy, including stretching and core exercises, can help with the ...

2. Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation - Mayo Clinic

   (The use of a stable dose of oral steroids post GVHD and/or topical steroids for ongoing skin GVHD is permitted with Medical Monitor approval.) Subjects who ...

3. Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer - Mayo Clinic

   Topical steroids or steroid eye drops are permitted. Uncontrolled intercurrent illness including, but not limited to: Ongoing or active infection; Symptomatic ...

4. Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma - Mayo Clinic

   Intranasal, inhaled, topical steroids, or local steroid injections;; Systemic corticosteroids at physiologic doses not to exceed 10mg/day of Prednisone or ...

5. A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors - Mayo Clinic

   Patients with rheumatoid arthritis and other rheumatologic arthropathies, Sjögren's syndrome and psoriasis controlled with topical medication only and ...

6. A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ - Mayo Clinic

   However, topical steroids, inhalants or steroid eye drops are permitted * Uncontrolled intercurrent illness including, but not limited to, ongoing or active ...

7. Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy - Mayo Clinic

   Immunosuppressive therapy (excluding topical steroids) for any other condition =< 4 weeks prior to registration; Persistent fever (> 24 hours) documented by ...

8. FORTIFI-HN01: A Study Of Ficerafusp Alfa (BCA101) Or Placebo In Combination With Pembrolizumab In First-Line PD-L1-pos, R Or M HNSCC - Mayo Clinic

   ... topical, intranasal, intrabronchial, or ocular steroids. * Use of a live or live attenuated vaccine within 4 weeks prior to Screening. Other Inclusion ...

9. Menopause: Ensuring a tranquil transition - Mayo Clinic News Network

   Some women may benefit from topical vaginal lubricants or moisturizers. What lifestyle modifications can I make to ease the transition of menopause? Women ...

10. A Study To Evaluate Intravenous Iloprost In Subjects With Symptomatic Raynaud's Phenomenon Secondary To Systemic Sclerosis - Mayo Clinic

    Subjects who have initiated or had a dose change of any of the following within 2 weeks of screening: oral, topical, or intravenous (IV) vasodilators (e.g. ...